Citations

Clear

28 citation(s) found for "Shariat, S".

Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes
Moschini, Marco , Zamboni, Stefania , Mathiéu, Romain , Xylinas, Évanguelos , Tan, Wei Shen , Kelly, John D. , Simone, Giuseppe , Meraney, Anoop, Krishna, Suprita, Konety, Badrinath R. , Mattei, Agostino , Baumeister, Philipp , Mordasini, Livio , Montorsi, Francesco , Briganti, Alberto , Sanchez‐Salas, Rafael , Cathelineau, Xavier , Rink, Michael , Karakiewicz, Pierre I. , Koupparis, Anthony , Kassouf, Wassim , Scherr, Douglas S. , Ploussard, Guillaume , Boorjian, Stephen A. , Sooriakumaran, Prasanna , Larcher, Alessandro , Simone, Giuseppe , Gallina, Andrea , Lotan, Yair , Moschini, Marco , Soria, Francesco , Baumeister, Philipp, Gallina, Andrea , Stabile, Armando , Necchi, Andrea , Rouprêt, Morgan , Lotan, Yair , Shariat, Shahrokh F.

Mayo Clinic

Journal of Clinical Medicine | August 9, 2019 | Volume: 8 | Issue: 8 | Pages: 1192

10.3390/jcm8081192 | PMID 31395826 Get It

Background: To assess the differential effect of robotic assisted radical cystectomy (RARC) versus open radical cystectomy (ORC) on survival outcomes in matched analyses performed on a large multicentric cohort. Methods: The study included 9757 patients with urothelial bladder cancer (BCa) treated in a consecutive manner at each of 25 institutions. All patients underwent radical cystectomy with bilateral pelvic lymphadenectomy. To adjust for potential selection bias, propensity score matching 2:1 was performed with two ORC patients matched to one RARC patient. The propensity-matched cohort included 1374 patients. Multivariable competing risk analyses accounting for death of other causes, tested association of surgical technique with recurrence and cancer specific mortality (CSM), before and after propensity score matching. Results: Overall, 767 (7.8%) patients underwent RARC and 8990 (92.2%) ORC. The median follow-up before and after propensity matching was 81 and 102 months, respectively. In the overall population, the 3-year recurrence rates and CSM were 37% vs. 26% and 34% vs. 24% for ORC vs. RARC (all p values > 0.1), respectively. On multivariable Cox regression analyses, RARC and ORC had similar recurrence and CSM rates before and after matching (all p values > 0.1). Conclusions: Patients treated with RARC and ORC have similar survival outcomes. This data is helpful in consulting patients until long term survival outcomes of level one evidence is available.
The role of cytoreductive radical prostatectomy (cRP) in men with hormone-sensitive, metastatic prostate cancer (mPCA).
Heidenreich, Axel , Montorsi, Francesco , Karnes, J., Shariat, Shahrokh F., Gandaglia, Giorgio , Briganti, Alberto , Fossati, Nicola , Suardi, Nazareno

Mayo Clinic

Journal of Clinical Oncology | March 29, 2017 | Volume: 35 | Issue: 6_suppl | Pages: 241-241

10.1200/jco.2017.35.6_suppl.241 Get It

241 Background: Androgen deprivation represents the standard treatment for PCA with osseous metastases. We explored the role of cRP in the largest cohort of contemporary patients with mPCA treated in 4 tertiary referral centres. Methods: A total of 114 patients with mPCA, lymph node, osseous or visceral metastases underwent cRP. Surgery related complications (Clavien-Dindo classification) and functional outcome were analysed. Oncologic outcome parameters such as cancer specific & overall survival as well as biochemical and clinical-free survival were evaluated using descriptive statistical analysis. Results: Mean patient age was 61 (42-69) years. Mean and median follow-up was 39.7 months (7-75) and 47 months (28-96), resp. 93 (81.6%) and 21 (18.4%) patients had low volume and high volume mets, resp.,. 80(70.2%) pts underwent neoadjuvant ADT with LHRH analogues. Surgical approach was open retropubic RP in 104 (92%) pts and 2 (1.8%), 10 (8.8%) and 101 (89.4%) pts underwent no, limited or extended pelvic LAD, resp. Adjuvant therapy was delivered in 99 (86.8%) pts. Pathohistology revealed significant vital PCA in 100% of cases: n = 16 (14.0%) exhibited pT4a, n = 21 (18.4%) had pT2 and the remainder had pT3a/b PCA. Positive lymph nodes or positive surgical margins were identified in 61.6% and 36.8%, resp.. 110 (96.5%) are alive and 66.7% are relapse-free. 74 (64.9%) pts did not experience any surgery related complications; 15 (13.1%) pts experienced Clavien Dindo grade IIIb/IV complications and underwent reintervention. Low versus high volume (32.2% vs 50%, p = 0.03), PSA at cRP < 1ng/ml vs PSA > 4 ng/ml, (18.9% vs 45.6%, p = 0.02) were associated with relapse. Low vs high volume disease (7.1% vs 32.1%), PSA < 4ng/ml vs PSA > 4 ng/ml (6.1% vs 47.8%) and neoadjuvant vs no neoadjuvant therapy (8.75% vs 24.2%) were associated with Clavien-Dindo IIIB complications (p < 0.05). Conclusions: cRP is feasible in men with mPCA independent on the extent of disease with a low rate of significant complications and good functional outcome. About two thirds of the patients remain relapse-free after a median follow-up of close to 4 years. cRP might be an individualized treatment option in the multimodality management of mPCA.
The impact of re‐transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high‐grade/Grade 3 bladder cancer treated with bacille Calmette–Guérin
Sylvester, Richard , Joniau, Steven , Oderda, Marco , Serretta, Vincenzo , Larré, S. , Stasi, Savino M. Di , Rhijn, Bas van, Witjes, Alfred, Grotenhuis, Anne J., Colombo, Renzo , Briganti, Alberto , Babjuk, Marek , Soukup, Viktor , Malats, Núria , Baniel, Jack, Cai, Tommaso , Cha, Eugene K., Ardelt, Peter, Vakarakis, John, Bartoletti, Riccardo , Dalbagni, Guido , Xylinas, Évanguelos , Karnes, R. Jeffrey , Palou, Joan, Karnes, Robert J, Gontero, Paolo , Pisano, Francesca , Malmström, Per‐Uno , Irani, Jacques , Mano, Roy , Cha, Eugene K., Shariat, Shahrokh F. , Malats, Nuria , Joniau, Steven , Oderda, Marco

Mayo Clinic

BJU International | October 15, 2015 | Volume: 118 | Issue: 1 | Pages: 44-52

10.1111/bju.13354 | PMID 26469362 Get It

Objectives To determine if a re‐transurethral resection (TUR), in the presence or absence of muscle at the first TUR in patients with T1‐high grade (HG)/Grade 3 (G3) bladder cancer, makes a difference in recurrence, progression, cancer specific (CSS) and overall survival (OS). Patients and methods In a large retrospective multicentre cohort of 2451 patients with T1‐HG/G3 initially treated with bacille Calmette–Guérin, 935 (38%) had a re‐TUR. According to the presence or absence of muscle in the specimen of the primary TUR, patients were divided in four groups: group 1 (no muscle, no re‐TUR), group 2 (no muscle, re‐TUR), group 3 (muscle, no re‐TUR) and group 4 (muscle, re‐TUR). Clinical outcomes were compared across the four groups. Results Re‐TUR had a positive impact on recurrence, progression, CSS and OS only if muscle was not present in the primary TUR specimen. Adjusting for the most important prognostic factors, re‐TUR in the absence of muscle had a borderline significant effect on time to recurrence [hazard ratio (HR) 0.67, P = 0.08], progression (HR 0.46, P = 0.06), CSS (HR 0.31, P = 0.07) and OS (HR 0.48, P = 0.05). Re‐TUR in the presence of muscle in the primary TUR specimen did not improve the outcome for any of the endpoints. Conclusions Our retrospective analysis suggests that re‐TUR may not be necessary in patients with T1‐HG/G3, if muscle is present in the specimen of the primary TUR.
Preoperative predictors of renal function decline after radical nephroureterectomy for upper tract urothelial carcinoma
Kaag, Matthew, Trost, Landon , Thompson, R. Houston, Favaretto, Ricardo L., Elliott, Vanessa, Maschino, Alexandra C., Vertosick, Emily , Dalbagni, Guido , Shariat, Shahrokh F. , Raman, Jay D. , Vertosick, Emily A

Mayo Clinic

BJU International | December 9, 2013 | Volume: 114 | Issue: 5 | Pages: 674-679

10.1111/bju.12597 | PMID 24314050 Get It

Objectives To model renal function after radical nephroureterectomy ( RNU ) for upper tract urothelial carcinoma ( UTUC ). To identify predictors of renal function decline after surgery, thereby allowing the identification of patients likely to be ineligible for cisplatin‐based chemotherapy in the adjuvant setting. Patients and Methods We retrospectively identified 374 patients treated with RNU for UTUC at three centres between 1995 and 2010. Estimated glomerular filtration rate ( eGFR ) was calculated using Chronic Kidney Disease Epidemiology Collaboration equation before RNU and at early (1–5 months after RNU ) and late (>5 months) time points after RNU . Only patients deemed eligible for cisplatin‐based chemotherapy before RNU (preoperative glomerular filtration rate [ GFR ] ≥60 mL/min/1.73 m 2 ) were included. Multivariable analysis identified the preoperative predictors of eGFR after RNU at early postoperative and late postoperative time points. Results A total of 163 patients had an eligible early post‐ RNU eGFR measurement and 172 had an eligible late eGFR measurement. The median eGFR declined by 32% and did not show a significant trend toward recovery over time ( P = 0.4). On multivariable analysis preoperative eGFR and patient age were significantly associated with early and late postoperative eGFR , while C harlson comorbidity index score was significantly associated with late postoperative eGFR alone. Conclusions In patients with normal preoperative eGFR (≥60 mL/min/1.73 m 2 ), renal function decreases by one‐third after RNU and does not show evidence of recovery over time. Elderly patients and those with pre‐ RNU eGFR closer to 60 mL/min/1.73 m 2 (lower eGFR in the present cohort) are more likely to be ineligible for adjuvant cisplatin‐based chemotherapy regimens because of renal function loss after RNU .
Impact of peri‐operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder
Kluth, Luis A. , Xylinas, Évanguelos , Rieken, Malte, Ghouayel, Maya El, Sun, Maxine , Karakiewicz, Pierre I. , Boorjian, Stephen A. , Lee, Richard K. , Briganti, Alberto , Fisch, Margit , Scherr, Douglas S. , Lotan, Yair , Chun, Felix K.‐H. , Rouprêt, Morgan , Shariat, Shahrokh F.

Mayo Clinic

BJU International | September 5, 2013 | Volume: 113 | Issue: 3 | Pages: 393-398

10.1111/bju.12439 | PMID 24053618 Get It

Objective To determine the association between peri‐operative blood transfusion ( PBT ) and oncological outcomes in a large multi‐institutional cohort of patients undergoing radical cystectomy ( RC ) for urothelial carcinoma of the bladder ( UCB ). Patients and Methods We conducted a retrospective analysis of 2895 patients treated with RC for UCB . Univariable and multivariable C ox regression models were used to analyse the effect of PBT administration on disease recurrence, cancer‐specific mortality, and any‐cause mortality. Results Patients' median (interquartile range [ IQR ]) age was 67 (60, 73) years and the median ( IQR ) follow‐up was 36.1 (15, 84) months. Patients who received PBT were more likely to have advanced disease ( P < 0.001), high grade tumours ( P = 0.047) and nodal metastasis ( P = 0.004). PBT was associated with a higher risk of disease recurrence ( P = 0.003), cancer‐specific mortality ( P = 0.017), and any‐cause mortality ( P = 0.010) in univariable, but not multivariable, analyses ( P > 0.05). In multivariable analyses, pathological tumour stage, pathological nodal stage, soft tissue surgical margin, lymphovascular invasion and administration of adjuvant chemotherapy were independent predictors of disease recurrence, cancer‐specific mortality and any‐cause mortality (all P values <0.002). Conclusions Patients with UCB who underwent RC and received PBT had a greater risk of disease recurrence, cancer‐specific mortality and any‐cause mortality in univariable, but not multivariable, analysis. Although the greater need for PBT with more advanced disease is probably caused by a number of factors, including surgical and cancer‐related factors, the present analysis showed that the disease characteristics rather than need for PBT led to worse outcomes.
Health care‐associated infections after major cancer surgery
Sammon, Jesse D. , Trinh, Vincent Quoc‐Huy , Ravi, Praful , Sukumar, Shyam, Gervais, Mai‐Kim , Larouche, Alexandre , Kim, Simon P. , Menon, Mani, Karakiewicz, Pierre I. , Sun, Maxine , Shariat, Shahrokh F. , Tian, Zhe Wen , Kowalczyk, Keith J. , Hu, Jim C. , Trinh, Quoc‐Dien

Mayo Clinic

Cancer | March 19, 2013 | Volume: 119 | Issue: 12 | Pages: 2317-2324

10.1002/cncr.28027 | PMID 23512473 Get It

BACKGROUNDApproximately 1.7 million individuals per year are affected with health care‐associated infections (HAIs) in the United States. The authors examined trends in the incidence of HAI after major cancer surgery (MCS) and risk factors for HAI to describe the effects of HAI on mortality after MCS.METHODSPatients undergoing 1 of 8 MCS procedures within the Nationwide Inpatient Sample between 1999 and 2009 were identified (n = 2,502,686). Generalized linear regression models were used to estimate the impact of the primary predictors (procedure type, age, sex, race, insurance status, Charlson comorbidity index, hospital volume, and hospital bed size) on the odds of HAI and in‐hospital mortality. Trends in incidence were evaluated with linear regression.RESULTSOverall, MCS‐associated HAI incidence increased 2.7% per year (P < .001), whereas mortality decreased 1.3% per year (P < .001). Male gender (odds ratio [OR], 1.12, 95% confidence interval [CI], 1.10‐1.14), advancing age (OR, 1.02; 95% CI, 1.02‐1.02), black race (OR, 1.26; 95% CI, 1.21‐1.31), ≥1 comorbidities (OR, from 1.08 [95% CI, 1.04‐1.13] to 1.31 [95% CI, 1.27‐1.35]), and nonprivate insurance (OR, from 1.18 [95% CI, 1.15‐1.22] to 1.67 [95% CI, 1.59‐1.76]) were associated with an increased odds of HAI on multivariable analysis. Conversely, increasing hospital volume was associated with lower odds of HAI (OR, 0.999; 95% CI, 0.99‐0.99). Patients with MCS‐associated HAI had increased odds of mortality (OR, 8.66; 95% CI, 8.51‐8.82).CONCLUSIONSBetween 1999 and 2009, the incidence of MCS‐associated HAI events increased; however, HAI‐associated mortality decreased. That said, significant disparities exist in the hospital and demographic attributes associated with MCS‐associated HAI, with attendant health policy implications. Moreover, HAI remains detrimentally linked to mortality during hospitalization. Cancer 2013;119:2317–2324. © 2013 American Cancer Society.